Tab. Corlift
Tablet · Oral · 2.5mg · 1 tablet
৳40
Other Presentations
Select another presentation of Corlift.
Tab. Corlift
10mg · 1 tablet
৳100
Tab. Corlift Current
2.5mg · 1 tablet
৳40
Tab. Corlift
5mg · 1 tablet
৳80
Tab.
Corlift
Vericiguat
— Ziska Pharmaceuticals Ltd.
2.5mg
· 1 tablet
Presentation
Tab. Corlift
Tablet · Oral · 2.5mg · 1 tablet
৳40
Dose rules
No structured dose rules are linked to this brand yet.
Dose reference
Human
Recommended Dosage: The recommended starting dose of Vericiguat is 2.5 mg orally once daily with food. Double the dose of Vericiguat approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the patient. For patients who are unable to swallow whole tablets, Vericiguat may be crushed and mixed with water immediately before administration.Pregnancy Testing in Females of Reproductive Potential: Obtain a pregnancy test in females of reproductive potential prior to initiating treatment with Vericiguat.Pediatric Use: Safety and effectiveness of Vericiguat have not been established in pediatric patients.
Clinical notes
Applications:
- Cardiovascular disease
Indication Notes:
Vericiguat is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.
Avoid In:
N/A
Contraindication Notes:
Vericiguat is contraindicated in patients with concomitant use of another soluble guanylate cyclase (sGC) stimulator. Vericiguat is contraindicated in pregnancy.
Vericiguat is a stimulator of soluble guanylate cyclase (sGC), an important enzyme in the nitric oxide (NO) signaling pathway. When NO binds to sGC, the enzyme catalyzes the synthesis of intracellular cyclic guanosine monophosphate (cGMP), a second messenger that plays a role in the regulation of vascular tone, and cardiac contractility, and cardiac remodeling. Heart failure is associated with impaired synthesis of NO and decreased activity of sGC, which may contribute to myocardial and vascular dysfunction. By directly stimulating sGC, independently of and synergistically with NO, vericiguat augments levels of intracellular cGMP, leading to smooth muscle relaxation and vasodilation.
Other Soluble Guanylate Cyclase Stimulators: Vericiguat is contraindicated in patients with concomitant use of another soluble guanylate cyclase (sGC) stimulator.PDE-5 Inhibitors: Concomitant use of Vericiguat with PDE-5 inhibitors is not recommended because of the potential for hypotension.
Based on data from animal reproduction studies, Vericiguat may cause fetal harm when administered to a pregnant woman and is contraindicated during pregnancy. There are no data on the presence of vericiguat in human milk, the effects on the breastfed infant, or the effects on milk production. Vericiguat is present in the milk of lactating rats and it is likely that vericiguat or its metabolites are present in human milk. Because of the potential for serious adverse reactions in breastfed infants from Vericiguat, advise women not to breastfeed during treatment with Vericiguat.
Based on data from animal reproduction studies, Vericiguat may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to a fetus. Obtain a pregnancy test before the start of treatment. Advise females of reproductive potential to use effective contraception during treatment with Vericiguat and for at least one month after the final dose.